This is the login page for PHARMA JAPAN WEB subscribers. PHARMA JAPAN WEB offers excerpts of some articles for free, but paid subscription is required to read full articles.

Today's Headlines RSS

ACADEMIA

Avigan’s Efficacy in Ebola “Unknown” with No Corroborative Data: NIID Official

There is no proof at this time that the anti-flu drug Avigan (favipiravir) is effective in treating patients infected with Ebola, but it should be used if the deadly virus ... > Read full story
REGULATORY
MHLW Warns of Hyperbilirubinemia in Patients on Sovriad (Nov.27)
REGULATORY
Panel Gives Green Light to Draft Report Calling for Legal Regulations for Clinical Research (Nov.27)
BUSINESS
ASKA Aims for 50% Share of Generic Candesartan Market through Blopress AG: President (Nov.27)
BUSINESS
Janssen Files NDA for Anticancer Agent Ibrutinib in Japan (Nov.27)
BUSINESS
Oncolys Files IND Application for Novel Cancer Treatment OBP-801 in US (Nov.27)
> More Latest News

Photosmore

  
ASKA Aims for 50% Share of Generic Candesartan Market through Blopress AG: President (Nov.27)Kaken Banking on Clenafin to Boost Dermatology Biz (Nov.27)Bulk Antibody Production Efficiency Up 10-fold, Production Costs Down “Several-fold” Since 2002: Chugai (Nov.26)
  
MSD to Ensure Appropriate Use of Insomnia Drug Belsomra (Nov.26)Potential Risk of Narcolepsy for Belsomra Should Be Thoroughly Communicated: Chuikyo (Nov.21)JPMA President Opposes Annual NHI Price Revision (Nov.21)

News Categories

REGULATORY
   MHLW Warns of Hyperbilirubinemia in Patients on Sovriad(Nov.27)
   Panel Gives Green Light to Draft Report Calling for Legal Regulations for Clinical Research(Nov.27)
   Cabinet OKs Regenerative Medicine Guidelines(Nov.26)
BUSINESS
   ASKA Aims for 50% Share of Generic Candesartan Market through Blopress AG: President(Nov.27)
   Janssen Files NDA for Anticancer Agent Ibrutinib in Japan(Nov.27)
   Oncolys Files IND Application for Novel Cancer Treatment OBP-801 in US(Nov.27)
ORGANIZATION
   JPMA President Opposes Annual NHI Price Revision(Nov.21)
   PhRMA Chair Prods Japan to Permanently Install Key Pricing Premium(Nov.20)
   Ihoken Proposes Revision of Compensation Guidelines to Include Compensation for Injury Due to Anticancer Drugs(Nov.20)
ACADEMIA
   Avigan’s Efficacy in Ebola “Unknown” with No Corroborative Data: NIID Official(Nov.27)
   J-CLEAR’s Kuwajima Criticizes Plan to Legally Regulate Clinical Research(Nov.12)
   ICH-GCP Compliance Obligatory for Clinical Studies Conducted by Chiba University(Oct.28)

Commentary

Torii Eager to Carve Out New Market with Japan’s 1st Sublingual Allergen Immunotherapy

Lexicon

PMDA-WEST:
医薬品医療機器総合機構関西支部

The Column

3 Reasons Why KOL Management Is No Longer Enough

Archives

Kaken Banking on Clenafin to Boost Dermatology Biz(Nov.27)
Bulk Antibody Production Efficiency Up 10-fold, Production Costs Down “Several-fold” Since 2002: Chugai(Nov.26)
Cabinet OKs Regenerative Medicine Guidelines(Nov.26)
Amgen Calls Off Clinical Studies of Rilotumumab for Gastric Cancer(Nov.26)
MSD to Ensure Appropriate Use of Insomnia Drug Belsomra(Nov.26)

Most Read

1.
Don’t Use Long-...
2.
CareNet Teams U...
3.
Top Two Japan U...
4.
PhRMA Chair Pro...
4.
3 Straight Year...

News Calendar